OHSU Presentation Template

advertisement
Emerging Trends in
Diagnostics and Therapeutics
ATA Corporate Leadership Council
Kathryn Schuff, MD, MCR
Opportunities in Clinical Thyroid Disease
Therapeutic Areas
Hypothyroidism
• Subclinical
hypothyroidism
• Hypothyroidism
• Hypothyroidism in
pregnancy
Hyperthyroidism
• Subclinical/overt
hyperthyroidism
• Graves opthalmopathy
Thyroid hormone responsive
diseases
Thyroid Nodules
• Thyroid nodule suppression
• Thyroid nodule ablation
Thyroid Cancer
• Thyroid remnant ablation
• RAI for thyroid cancer therapy
• Advanced thyroid cancer
Opportunities in Clinical Thyroid Disease
Diagnostic Areas
Genetics
• Genetic risk of AITD, CA
• Newborn screening
• Genetic variants predicting
response to LT4
Thyroid hormone
assessment
• Newborn screening
• T4, T3 assessments
• Thyroid hormone
‘bioassay’
Molecular Diagnostics
• Evaluation of thyroid
nodules
• Thyroid Ca risk stratification
• Thyroid Ca tumor marker
surveillance
Imaging
• Thyroid Ca imaging
Subclinical Hypothyroidism
Yes, that TSH is abnormal… But does it matter?
Impact of SCH: Nonalcoholic Fatty Liver Disease
• NAFLD is a common disorder: 20% of US
• Manifests as: Steatosis
Nonalcoholic steatohepatitis (NASH)
Progression to cirrhosis in 20%
Hepatocellular Carcinoma
• “Hepatic manifestation of metabolic syndrome”
• Cross-sectional case-control study
• 2324 hypothyroid - age/gender matched
• NAFLD defined by u/s, excl ETOH, Hep B/C
Chung Ge, J Hepatol 2012;57:150
NAFLD not simply due to worsened
metabolic syndrome – stratified analysis
Chung Ge, J Hepatol 2012;57:150
‘Dose-response’ in NAFLD
•
•
•
•
Increasing risk of NAFLD with higher TSH
Clinical implications not yet clear– RCT needed
May influence overall decision to treat SCH
?Target for TH analogues
Subclinical Hypothyroidism Clinical Trial Design
• RCTs of endogenous SCH: Difficult recruitment
– Lots of patients, but unwilling to be randomized
– Normalization of TSH/‘Regression to mean’
• Experimentally-induced SCH
–
–
–
–
Randomize LT4 treated to desired target ranges
Lots of LT4 treated patients
Interested in seeing what effects there are
Randomized, parallel arm study targeting:
TSH Range (mU/L)
Lower normal
limit
Proposed upper
normal limit
Current upper
normal limit
Consensus threshold
for treatment
0.28
2.5
5.0
10.0
Theoretical optimal
TSH range
High-normal TSH
Mildly elevated TSH
Mild Hypothyroidism
Hypothyroidism
Questions in the Treatment of Hypothyroidism
Diagnostics and Therapeutics
• Why are patients so unhappy with levothyroxine?
• Can we test for polymorphisms that predict
response to LT4 vs. T3 therapy?
• Do we need a thyroid hormone bioassay (other
than TSH)?
• Do patients gain (more) weight on LT4 therapy?
• Why don’t we yet have a sustained release
preparation of 16:1 LT4/LT3 + ‘other thyroid stuff’?
• What is the ‘other thyroid stuff’? T1AM?
Questions in the Treatment of Hypothyroidism
Diagnostics and Therapeutics
• Is there opportunity to modulate the process of
AITD?
• What does isolated hypothyroxinemia mean for
pregnant and nonpregnant patients?
• Do TPO+ pregnant women benefit from LT4?
• At what level of TSH and for what outcomes do
pregnant women benefit from LT4?
• Its’ so simple – why can’t we ensure iodine
sufficiency?
Thyroid responsive
diseases
Thyroid Hormone Analogues - Hyperlipidemia
•
•
•
•
•
•
•
•
168 patients, 12 wk
Eprotirome + statin
No change in TSH
T4 ↓ 22-34%
FT4 ↓ 12-21% WNL
LDL ↓ 12-32%
TG ↓ 16-33%
Lp(a) ↓ 10-43%
Further development halted
due to cartilage defects in
preclinical studies
Ladenson P. N Engl J Med 2010;11:906
Thyroid Hormone Analogues –
X-linked Adrenoleukodystrophy
• X-ALD: Genetic loss of the
ABCD1 gene results in LCFA
accumulation, neurologic damage
• Three other ABCD genes
• Sobetirome activates ABCD2
• Novel paradigm: Pharmacologic
approach to genetic
complementation
• Phase I dose escalation trial
imminent launch at OHSU
Genin J Steroid Biochem Mol Biol 2009;116:39
Thyroid Nodules
The Evolving Evaluation of the Nodule:
First DNA, then RNA, next proteomics?
BRAF testing + U/S + cytology improves DA
• 991 nodules
–60% benign
–22% indeterm
–17% malignant
Lee EJ. Clin Endocrinol 2011;75:844
The Evolving Evaluation of the Nodule:
First DNA, then RNA, next proteomics?
•
•
•
•
Focus on 497 indeterminate nodules
DNA Mutation panel: BRAF, RAS, RET/PTC, PAX8/PPARγ
Improves identification ‘benign’ subset of nodules
If negative:
Reference
The Evolving Evaluation of the Nodule:
First DNA, then RNA, next proteomics?
•
•
•
•
•
•
•
Focus on 265 nodules indeterminate FNA
85 malignant, 180 benign on final histology
Affirma gene expression classifier analysis
RNA microarray – 162 genes
Training set, validation set
Correctly identified 78 of 85 malignancies
6 of 7 FN showed low yield on FNA
– Generalization issue
Alexander EK. N Engl J Med 2012;367:8
Affirma gene classifier improves
classification of indeterminant nodules
Cytologic diagnosis:
AUS/FLUS
FN/SFN
SMC
NPV:
95%
94%
85%
Allows observation of nodules with AUS/FLUS or
FN/SFN + ‘Benign’ gene classifier
(risk of Ca similar to benign cytology)
DNA+RNA: Addition of BRAF testing does not
improve operating characteristics
The Evolving Evaluation of the Nodule:
First DNA, then RNA, next proteomics?
• Evaluation of panel of miRNAs defines
miRNA signature
• Training set of 60 FNA “AUS”
• Validation set of 68 FNA
• Good performance in PTC, but difficulty
with FTC/FAs
Shen R. Thyroid 2012;22:9
The Evolving Evaluation of the Nodule:
First DNA, then RNA, next proteomics?
Optimizing RAI for Multinodular Goiter
Use of Modified release rhTSH
• 95 pts MNG – avg size 96 ml (32 – 242 ml)
• Randomized placebo vs. 0.01 mg vs. 0.03 mg
• Treated with RAI
• Outcome: change in thyroid volume at 6 mo
Responder: 28% or greater ↓ in volume
• Secondary: trachea cross-sectional area,
TFTs, thyroid sx, EKG
Graf H. JCEM 2011;96:1368
Improved reduction in thyroid volume
with 0.03 mg MRrhTSH than lower dose
or RAI alone
• More ‘responders’ (64%
vs. 25% placebo)
• More hyperthyroid
symptoms, but tolerated
(18-26% vs. 3%)
• More neck pain
(18% vs. 10%)
• More hypothyroidism
(24% vs. 6%)
Graf H. JCEM 2011;96:1368
Thyroid Cancer
Adjunctive RAI for Low Risk Thyroid Ca:
30 mCi vs. 100 mCi
# evaluable patients
421
684
T1-3, N0-1, M0
T1N0-1,T2-3N0, M0
6-9 mo rhTSH or
THW scan <0.1%
8 mo neck u/s, rhTSH
Tg <1 ng/mL or -scan
Ablation rate: 30 vs. 100 mCi
85.0 vs. 88.9%
87.1 vs. 86.7%
Ablation rate: rhTSH vs. THW
87.1 vs. 86.7%
91.7 vs. 92.9%
Citation: NEJM 2012, Vol. 366
Mallick, p. 674
Schlumberger, p. 1663
Staging
Definition of successful
ablation
• Equivalence of low dose, high dose RAI and
method of preparation rhTSH, THW
• Short-term risks: Sialoadenitis, -cytopenias
• Long-term risks: Secondary malignancies
No impact of RAI in low risk thyroid Ca
HR
CI
P-value
OS
1.92
1.20 - 3.07
0.007
DFS
1.86
1.27 – 2.74
0.002
OS
0.69
0.37 – 1.29
0.243
DFS
0.73
0.43 – 1.25
0.259
Propensity
OS
0.75
0.4 – 1.38
0.352
stratified
DFS
1.11
0.73 – 1.70
0.48
Univariate
Multivariate
• 1298 low risk thyroid cancer patients
• 10.3 years median f/u
• 987 adjunctive RAI, 387 no RAI
Schvartz C. J Clin Endocrinol Metab 2012;97:1526
What is optimal surveillance for low risk
thyroid cancer?
# patients
278
1010
203
12 mo stim Tg
undetectable
12 mo stim Tg
undetectable
6-12 mo stim Tg
<2
6.3 years
7 years
8.5 years
Clinical
recurrence
2%
1.3%
3.9% at 5 yr
NPV of 12 mo
stim Tg
98%
98%
96%
Definition of
initial remission
Duration of f/u
NPV of second
stim Tg
100% at 2 year
Recurrence
details
½ of stim Tg+
had no clinical
recurrence
100% at 5 year
Only ½ of
recurrences found
by stim Tg+
1/3 of stim Tg +
had no clinical
recurrence
Han JM. Thyroid 2012;22:784
Rosario PW. Thyroid 2012; 22: 482
Klubo-Gwiezdzinska JK. Clin Endocrinol 2011;74:111
What is optimal surveillance for low risk
thyroid cancer?
• Undetectable rhTSH stimulated Tg predicts low risk
of clinical recurrence
• Improved NPV by repeat rhTSH stim Tg at 2 or 5 yr
• About half of +stim Tg are not clinical recurrences
• Some clinical recurrences not detected by stim Tg
• Not clear that stim Tg improves detection of
recurrences
• Same limitations will apply to ultrasensitive Tg
assays
TKI du jour
Perez CA, Biologics: Targets and Therapy 2012;6
TKI du jour – Emerging concepts and issues
Perez CA, Biologics: Targets and Therapy 2012;6
•
•
•
•
Stratification by mutational status
Combination therapy
Difficulty of RCTs competing with off-label use
Outcomes for ‘static’ therapy – RECIST vs. clinical
benefit
Ferengi Rules of Acquisition
#9: Opportunity plus instinct equals profit…
#58: There is no substitute for success…
Download
Related flashcards

Cancer organizations

24 cards

Tumor markers

15 cards

Cancer hospitals

29 cards

Oncology journals

71 cards

American oncologists

54 cards

Create Flashcards